A Phase 2 Randomized Study of LY2541546 versus Placebo in Postmenopausal Women with Low Bone Mineral Density:An Evaluation of the Dose Response Relationship Using Bone Mineral Density

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221242

Enrollment

Unknown

Registered

2010-09-17

Start date

2010-09-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

investigational material(s) Generic name etc : LY2541546 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigat

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Have low BMD, defined as a T-score for lumbar spine of between -3.5 and -2.0, inclusive, based on the local DXA report as interpreted by the investigator. The method of determining Tscore values will be based on regional standards. Three of 4 vertebrae, L1 through L4, must be evaluable for BMD scoring, as measure by DXA.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026